scholarly journals Highly accelerated first-pass contrast-enhanced magnetic resonance angiography of the peripheral vasculature: Comparison of gadofosveset trisodium with gadopentetate dimeglumine contrast agents

2009 ◽  
Vol 30 (5) ◽  
pp. 1085-1092 ◽  
Author(s):  
Jeffrey H. Maki ◽  
Maisie Wang ◽  
Gregory J. Wilson ◽  
Matthew G. Shutske ◽  
Tim Leiner
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Angiography ◽  
Contrast Agents ◽  
Gadopentetate Dimeglumine ◽  
Peripheral Vasculature ◽  
Gadofosveset Trisodium ◽  
Contrast Enhanced ◽  
First Pass

scholarly journals Contrast-Enhanced Magnetic Resonance Angiography Using a Novel Elastin-Specific Molecular Probe in an Experimental Animal Model

2018 ◽  
Vol 2018 ◽  
pp. 1-9 ◽  
Author(s):  
Carolin Reimann ◽  
Julia Brangsch ◽  
Jan Ole Kaufmann ◽  
Lisa C. Adams ◽  
David C. Onthank ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Image Quality ◽  
Magnetic Resonance Angiography ◽  
Contrast Agent ◽  
Mr Angiography ◽  
Molecular Probe ◽  
Time Resolved ◽  
Clinical Dose ◽  
Contrast Enhanced ◽  
First Pass

Objectives. The aim of this study was to test the potential of a new elastin-specific molecular agent for the performance of contrast-enhanced first-pass and 3D magnetic resonance angiography (MRA), compared to a clinically used extravascular contrast agent (gadobutrol) and based on clinical MR sequences. Materials and Methods. Eight C57BL/6J mice (BL6, male, aged 10 weeks) underwent a contrast-enhanced first-pass and 3D MR angiography (MRA) of the aorta and its main branches. All examinations were on a clinical 3 Tesla MR system (Siemens Healthcare, Erlangen, Germany). The clinical dose of 0.1 mmol/kg was administered in both probes. First, a time-resolved MRA (TWIST) was acquired during the first-pass to assess the arrival and washout of the contrast agent bolus. Subsequently, a high-resolution 3D MRA sequence (3D T1 FLASH) was acquired. Signal-to-noise ratios (SNRs) and contrast-to-noise ratios (CNRs) were calculated for all sequences. Results. The elastin-specific MR probe and the extravascular imaging agent (gadobutrol) enable high-quality MR angiograms in all animals. During the first-pass, the probes demonstrated a comparable peak enhancement (300.6 ± 32.9 vs. 288.5 ± 33.1, p>0.05). Following the bolus phase, both agents showed a comparable intravascular enhancement (SNR: 106.7 ± 11 vs. 102.3 ± 5.3; CNR 64.5 ± 7.4 vs. 61.1 ± 7.2, p>0.05). Both agents resulted in a high image quality with no statistical difference (p>0.05). Conclusion. The novel elastin-specific molecular probe enables the performance of first-pass and late 3D MR angiography with an intravascular contrast enhancement and image quality comparable to a clinically used extravascular contrast agent.

First-pass and steady-state magnetic resonance angiography of the thoracic vasculature using gadofosveset trisodium

2009 ◽  
Vol 30 (4) ◽  
pp. 809-816 ◽  
Author(s):  
Claas P. Naehle ◽  
Andreas Müller ◽  
Winfried A. Willinek ◽  
Carsten Meyer ◽  
Tobias Hestermann ◽  
...  
Keyword(s):  
Steady State ◽  
Magnetic Resonance ◽  
Magnetic Resonance Angiography ◽  
Gadofosveset Trisodium ◽  
First Pass

Spurious Hypocalcemia After Omniscan- or OptiMARK-Enhanced Magnetic Resonance Imaging: An Algorithm for Minimizing a False-Positive Laboratory Value

2004 ◽  
Vol 128 (10) ◽  
pp. 1151-1156
Author(s):  
Jane Emerson ◽  
Gerald Kost
Keyword(s):  
Magnetic Resonance Imaging ◽  
Magnetic Resonance ◽  
Contrast Agents ◽  
Calcium Level ◽  
Gadopentetate Dimeglumine ◽  
Total Calcium ◽  
Resonance Imaging ◽  
Contrast Enhanced ◽  
Calcium Measurement

Abstract Contrast-enhanced magnetic resonance imaging has become a routine diagnostic imaging procedure. Reports in the literature document that 2 of the 4 available gadolinium-based magnetic resonance imaging contrast agents, gadodiamide (Omniscan) and gadoversetamide (OptiMARK), are less stable and readily undergo dechelation. In vitro, this dechelation can result in interference with the most common laboratory methods used to measure total plasma or serum calcium. The result of total calcium measurement soon after contrast-enhanced magnetic resonance imaging with these interfering contrast agents is a spurious lowering of the total calcium level. This low calcium measurement may result in a value consistent with hypocalcemia and can persist in patients with renal insufficiency and in patients receiving higher doses of contrast agent. Alternatively, a clinically significant elevated calcium level may be overlooked because of the artificially lowered value. Two of the available gadolinium-based contrast agents, gadoteridol (ProHance) and gadopentetate dimeglumine (Magnevist), have not been to shown to interfere with total calcium measurement. A clinical practice algorithm for the laboratorian, the radiologist, and the clinician is presented to minimize the occurrence and consequences of a spuriously lowered total calcium level due to Omniscan- or OptiMARK-enhanced magnetic resonance imaging.

First-Pass Whole-Body Magnetic Resonance Angiography (MRA) Using the Blood-Pool Contrast Medium Gadofosveset Trisodium

2007 ◽  
Vol 42 (9) ◽  
pp. 659-664 ◽  
Author(s):  
Christian Klessen ◽  
Patrick A. Hein ◽  
Alexander Huppertz ◽  
Matthias Voth ◽  
Moritz Wagner ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Angiography ◽  
Contrast Medium ◽  
Blood Pool ◽  
Whole Body ◽  
Gadofosveset Trisodium ◽  
First Pass
Sign in / Sign up

Export Citation Format

Share Document